NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma develops obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in patients with cardiovascular disease risk.
SCHEDULE 13G/ANov 16Latest SEC filing
Oct 2Latest story
October 2026
September 2026
August 2026
July 2026